[Skip to Navigation]
Comment & Response
July 2014

Estimating Overdiagnosis in Lung Cancer Screening

Author Affiliations
  • 1Service de Pneumologie Aiguë Spécialisée et Cancérologie Thoracique, CH Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
  • 2Faculté de Médecine Lyon-Sud, Université Lyon 1, Oullins, France
  • 3Aix Marseille Univ–Assistance Publique–Hôpitaux de Marseille, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, France
  • 4Respiratory Disease Department, Tenon Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
  • 5Intergroupe Francophone de Cancérologie Thoracique (IFCT), Paris, France
JAMA Intern Med. 2014;174(7):1197. doi:10.1001/jamainternmed.2014.1532

To the Editor We read with interest the article by Patz et al1 investigating overdiagnosis in the National Lung Screening Trial (NLST). In their investigation, the authors found the upper bound for probability of overdiagnosis to be 11.0% to 18.5% for all lung cancers and even higher for bronchioloalveolar carcinoma (BAC) (67.6% to 78.9%). However, this risk assessment did not consider the lead- and the length-time biases.2

Add or change institution